Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | PPP1CA | P62136 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | RPA1 | P27694 | 7/20 | 0.62 |
| ▸ | MARS1 | P56192 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488941 | 0.91 | KMT2A (0.82) | KMT2AMEN1PPP1CASMN1; SMN2RPA1 | |
| SCHEMBL1514517 | 0.90 | KMT2A (0.81) | KMT2AMEN1PPP1CASMN1; SMN2RPA1 | |
| SCHEMBL1514551 | 0.86 | RPA1 (0.76) | KMT2AMEN1PPP1CARPA1 | |
| SCHEMBL1514727 | 0.83 | KMT2A (0.71) | KMT2AMEN1PPP1CASMN1; SMN2RPA1 | |
| SCHEMBL1514335 | 0.82 | RPA1 (0.80) | KMT2AMEN1PPP1CASMN1; SMN2RPA1 | |
| SCHEMBL12000521 | 0.80 | KMT2A (0.66) | KMT2AMEN1PPP1CASMN1; SMN2RPA1 | |
| SCHEMBL14728132 | 0.79 | SMN1; SMN2 (0.86) | KMT2AMEN1PPP1CASMN1; SMN2RPA1 | |
| SCHEMBL1940302 | 0.78 | KMT2A (0.64) | KMT2AMEN1PPP1CARPA1MARS1 | |
| Hydrochloric Acid SCHEMBL8742176 | 0.78 | SMN1; SMN2 (0.97) | KMT2AMEN1PPP1CASMN1; SMN2RPA1 | |
| SCHEMBL1514553 | 0.77 | MARS1 (0.73) | KMT2AMEN1PPP1CARPA1MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | KMT2A 1216/4885MEN1 4495/4885PPP1CA 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.